Comparison · NCT02655653-c8c6f6cd
Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Mortality Within 30 Days Post-operation
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Epsilon-aminocaproic Acid (EACA) vs Tranexamic Acid (TA): Mortality Within 30 Days Post-operation. Trial comparisons, record NCT02655653-c8c6f6cd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02655653-c8c6f6cd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0179 | 0.00316 | 0.0945 | wilson | |
| Risk in group 2 | 0.0172 | 0.00305 | 0.0914 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000616 | -0.075 | 0.0785 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.0664 | 16.2 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.0632 | 17 | log | |
| Number needed to treat, for one more participant with the outcome on Epsilon-aminocaproic Acid (EACA) than on Tranexamic Acid (TA) | 1,620 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Epsilon-aminocaproic Acid (EACA) | How many subjects passed away? | 1 | 56 | OG000 |
| Group 2 | Tranexamic Acid (TA) | How many subjects passed away? | 1 | 58 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Mortality Within 30 Days Post-operation
- Description
- Time frame
- Within 30 days after surgery
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
- NCT number
- NCT02655653
- Phases
- PHASE3
- Conditions
- Bleeding
- Interventions
- Epsilon-aminocaproic acid administered, Tranexamic Acid administered
- Lead sponsor
- Montefiore Medical Center
- Results first posted
- 2020-06-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02655653?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02655653-c8c6f6cd